SNX-482 vs Apratoxin A
Head-to-head comparison of SNX-482 (SNX-482 peptide from Hysterocrates gigas venom) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | SNX-482 | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | SNX-482 peptide from Hysterocrates gigas venom | Apratoxin A |
| Molecular Weight | 4,300 Da | N/A |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 41 | N/A |
| Typical Dose | 0.01-1 nmol intrathecal|1-100 nM in vitro|single-dose electrophysiology studies | N/A in humans; nanomolar in vitro |
| Route | Intrathecal | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 140 |
| Research Status | Pre-clinical | Pre-clinical |
SNX-482 Benefits
- ✓Cav2.3 blockade
- ✓synaptic transmission studies
- ✓excitability mapping
- ✓pain and epilepsy research
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
SNX-482 Dosing
Patch-clamp Cav2.3 assays|Intrathecal neurophysiology studies|Acute channel-blockade experiments
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
SNX-482 Side Effects
- ⚠Ataxia at high exposure
- ⚠off-target calcium-channel block
- ⚠cardiovascular effects in animal models
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
SNX-482
SNX-482 has been used to dissect R-type calcium currents in neurons and endocrine cells, and to map the role of Cav2.3 in excitability. Its selectivity profile has made it a standard research reagent in channel pharmacology.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.